Menopause and HRT: The Conversation Indian Women Deserve to Have

The fear around hormone replacement therapy has kept millions of women suffering unnecessarily. Here is what the current evidence actually says — and what I tell my patients.

By Dr. Neha Sain · Gynaecologist, MS (Obstetrics & Gynaecology)

There is a question I am asked almost every week in some form: "Is HRT safe?" And my honest answer is: for the majority of women, when started at the right time, with modern formulations, yes — and the evidence for this is substantially stronger than the evidence against it.

But that answer needs context. Because the fear that many women (and some doctors) have around hormone replacement therapy is not irrational — it was generated by a very influential study that was later found to be significantly flawed. And that fear has had a real cost: decades of women suffering through menopausal symptoms that were treatable, told that the treatment was too dangerous, and left to manage.

Let me take you through what we actually know.

What menopause is and what it does to the body

Menopause is the permanent cessation of menstruation, confirmed after 12 consecutive months without a period. The average age of menopause in Indian women is 46–47 years — approximately two years earlier than the global average, for reasons that are likely related to nutritional and socioeconomic factors across the lifespan.

Perimenopause — the transitional period — begins when the ovaries start producing less oestrogen reliably. This can begin four to eight years before the final period, often in the early forties. The hormonal fluctuations of perimenopause are often more dramatic and disruptive than those of established menopause itself, which is why many women describe perimenopause as the harder phase.

Oestrogen is not simply a reproductive hormone. It has receptors throughout the body — in the brain, cardiovascular system, bone, skin, urinary tract, and vagina. When oestrogen levels fall, all of these systems are affected.

The symptoms — including the ones nobody talks about

Vasomotor symptoms — hot flushes and night sweats — are the most discussed. They affect approximately 75–80% of menopausal women and can range from a mild warmth to a drenching, sleep-destroying event that occurs multiple times per hour. For some women they last for one to two years; for a significant proportion, they last for a decade or more.

Genitourinary Syndrome of Menopause (GSM) is the term for the cluster of changes that occur in the vulva, vagina, and lower urinary tract as a result of oestrogen deficiency — and it is the most under-reported and under-treated aspect of menopause. Vaginal dryness, burning, itching, pain during sex, urinary urgency and frequency, and recurrent urinary tract infections are all manifestations of GSM. Unlike vasomotor symptoms, which tend to improve over time, GSM worsens progressively if untreated. In my clinic, I consistently find that women have been suffering with these symptoms for years before mentioning them.

Cognitive and mood changes. Brain fog — difficulty finding words, slower thinking, lapses in memory — is reported by the majority of peri and postmenopausal women and is a direct effect of oestrogen withdrawal on the brain. Irritability, anxiety (often new-onset, in women with no prior anxiety history), low mood, and a sense of not recognising oneself are all common and all hormonally driven.

Bone loss. In the first three to five years after menopause, bone mineral density declines at a rate of 2–3% per year — faster than at any other point in a woman's life. Osteoporosis and its consequence, fragility fractures, are a major cause of disability and loss of independence in Indian women over 60. This is not a cosmetic problem; it is a long-term health risk that begins at menopause.

Cardiovascular risk. Before menopause, oestrogen is cardioprotective — it maintains favourable cholesterol ratios and arterial flexibility. After menopause, cardiovascular risk rises steeply, and by their sixties, women's heart disease rates approach those of men. This is one of the most important and least discussed consequences of oestrogen deficiency.

The HRT story: what happened and what the evidence actually shows

In 2002, the Women's Health Initiative (WHI) study published results suggesting that HRT increased the risk of breast cancer, blood clots, stroke, and heart disease. The headlines were dramatic, HRT prescribing collapsed almost overnight, and a generation of women was effectively told that the treatment for their menopausal symptoms was too dangerous to use.

What has become clear in the decades since is that the WHI study was significantly flawed in its applicability to the typical menopausal patient. The average age of participants was 63 — well beyond the menopause transition. Many had pre-existing cardiovascular risk factors. The formulation used was conjugated equine oestrogen combined with medroxyprogesterone acetate — an older, synthetic progestogen that is no longer considered the preferred option.

Current evidence, synthesised in guidelines from the British Menopause Society, the International Menopause Society, and the North American Menopause Society, reaches a different conclusion: for women who start HRT before the age of 60, or within ten years of menopause, and who do not have specific contraindications, the benefits of treatment significantly outweigh the risks for most women.

The key points:

Breast cancer risk is smaller than the original WHI suggested — and it is largely related to the type of progestogen used. Modern body-identical progesterone (micronised progesterone, available in India as Utrogestan and generic equivalents) carries a substantially lower breast cancer risk than the synthetic progestogens used in the WHI.

Transdermal oestrogen (delivered as a gel, patch, or spray through the skin) does not carry the same blood clot and stroke risk as oral oestrogen. The clot risk associated with oral oestrogen is real; the clot risk associated with transdermal oestrogen is not — it bypasses first-pass liver metabolism and does not activate clotting pathways in the same way.

HRT started within the "window of opportunity" — within ten years of menopause — actually reduces cardiovascular risk and may reduce the risk of type 2 diabetes, osteoporosis, and, emerging evidence suggests, dementia.

Topical vaginal oestrogen — pessaries, cream, or ring — treats GSM with negligible systemic absorption and is considered safe even for women with a history of oestrogen-sensitive breast cancer (though this should be discussed with the treating oncologist).

Who should not take HRT

There are genuine contraindications: a personal history of oestrogen-receptor-positive breast cancer (where the decision should be made in consultation with your oncologist), unexplained vaginal bleeding, active liver disease, or a recent blood clot. For women with these histories, non-hormonal alternatives and local vaginal oestrogen can often still be used.

What I tell my patients

The decision about HRT is individual. It depends on your symptom severity, your personal and family health history, your bone density, your cardiovascular risk, and your priorities. What it should not depend on is fear based on a study from 2002 that was conducted in a different population with a different formulation.

If your menopausal symptoms are affecting your quality of life — your sleep, your relationships, your work, your sense of self — you deserve an honest conversation about your options. Not reassurance that it will pass. Not dismissal of your symptoms as a natural part of aging. An honest clinical conversation.

You can have that conversation with me through a Smart Consultation. Share your symptom picture, your health history, and your questions — and I will give you a clear, evidence-based assessment.